spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

ROUSSELOT INTRODUCES X-PURE® GelMA FOR TRANSLATIONAL MEDICINE

Rousselot


Irving, United States [03 June 2020] — Rousselot, a Darling Ingredients brand and the global leader of collagen-based solutions, takes on the digital challenge and introduces X-Pure® GelMA at Bio Digital 2020. The first GMP-ready range of gelatin methacryloyl (GelMA) biomaterials suitable for preclinical and clinical applications, X-Pure® GelMA is part of the X-Pure portfolio of ultra-pure gelatins and collagens, suitable for use as biomaterials in 3D bioprinting, tissue engineering, and regenerative medicine.

GelMA, the most versatile biological environment for cells
Methacryloyl is a commonly used crosslinker, important to increase the melting point and mechanical strength of gelatin-based constructs. In GelMA hydrogels, the inherent bioactivity, biodegradability, and cell compatibility of gelatin are combined with the tailorability of photo-crosslinking. This combination holds a huge potential for the creation of tunable biological environments for the culture of various eukaryotic cells at body temperature.

X-Pure GelMA - The first GMP-ready gelatin methacryloyl
GelMA-oriented patent applications have been growing exponentially over the last 5 years, with many of these research concepts now being translated into the clinic. However, standard GelMA products often carry high and variable levels of soluble impurities originating from either the gelatin raw material or the chemical synthesis process. The presence of these impurities such as endotoxins and/or MA residues are detrimental for in-body use but can also affect the success of in vitro applications.

Rousselot’s unique purification process, centered around a two-stage routine, results in ultra-low levels of pyrogens and residual methacrylic acid, providing an excellent safety profile to the product. Further, consistent batch-to batch quality ensures reliable results and shorter lead times to the clinic.

Readily available, X-Pure GelMA can be produced in compliance with GMP regulatory requirements for quality, raw material sourcing, and documentation for approval across all major regulators worldwide, thereby minimizing regulatory risks and optimizing the pace of product development.

With full and validated traceability of raw materials, and with ultra-low levels of impurities such as pyrogens and methacrylic acid, X-Pure GelMA can significantly reduce time to clinic”, explains Tanja Vervust, Global Director Rousselot Biomedical. ‘Rousselot’s global presence and biomaterials expertise enable access to an extensive IP portfolio as well as a reliable security of supply, providing real added value to the high purity of the new range.’

The new range covers a broad choice of molecular weights and modification degrees of gelatin methacryloyl biomaterials. This allows close collaboration with customers to determine the right specifications to accurately produce custom-made solutions.
phone +31 499 364100
email Gelatin@rousselot.com
web www.rousselot.com
email Rousselot BV, Kanaaldijk Noord 20 5691 NM SON
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Stability Testing and Forced Degradation Stress Tests - Proactive Risk Management

Whereas the durability of many consumables, have a strong tendency to decrease, stability is and remains a crucial factor for pharmaceuticals. That is why the identification and elimination of factors, which put long-term stability at risk, is central during development – and an important requirement concerning the product’s quality.
More info >>


White Papers

The Emerging Use of Social Media in Orphan Disease Drug Research

Worldwide Clinical Trials Ltd

The use of various social media platforms, such as Twitter, Instagram, Facebook, and LinkedIn, for dissemination of clinical trial information has created a cornucopia of possibilities enabling clinical trial performance. Characterized by a people-to-people immediacy, social media permits extraordinarily adaptive modification of study information in real-time, and it does so in a highly targeted fashion.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement